High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib

被引：7
作者：
Kuiper, J. L. [1 ]
Heideman, D. A. M. [2 ]
Thunnissen, E. [2 ]
van Wijk, A. W. [1 ]
Postmus, P. E. [1 ]
Smit, E. F. [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Pulm Dis, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷 / 07期
关键词：
FACTOR RECEPTOR MUTATION; LEPTOMENINGEAL METASTASES; IMATINIB MESYLATE; RESISTANCE; THERAPY;
D O I：
10.1016/j.ejca.2014.02.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1399 / 1401
页数：3
相关论文
共 11 条
  • [1] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632
  • [2] High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
    Clarke, Jennifer L.
    Pao, William
    Wu, Nian
    Miller, Vincent A.
    Lassman, Andrew B.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2010, 99 (02) : 283 - 286
  • [3] "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Grommes, Christian
    Oxnard, Geoffrey R.
    Kris, Mark G.
    Miller, Vincent A.
    Pao, William
    Holodny, Andrei I.
    Clarke, Jennifer L.
    Lassman, Andrew B.
    [J]. NEURO-ONCOLOGY, 2011, 13 (12) : 1364 - 1369
  • [4] High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer
    Hata, Akito
    Kaji, Reiko
    Fujita, Shiro
    Katakami, Nobuyuki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) : 653 - 654
  • [5] Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
    Jackman, David M.
    Holmes, Alison J.
    Lindeman, Neal
    Wen, Patrick Y.
    Kesari, Santosh
    Borras, Ana M.
    Bailey, Christopher
    de Jong, Francisca
    Jaenne, Pasi A.
    Johnson, Bruce E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4517 - 4520
  • [6] Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
    Kantarjian, HM
    Talpaz, M
    O'Brien, S
    Giles, F
    Garcia-Manero, G
    Faderl, S
    Thomas, D
    Shan, JQ
    Rios, MB
    Cortes, J
    [J]. BLOOD, 2003, 101 (02) : 473 - 475
  • [7] High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well
    Kuiper, J. L.
    Smit, E. F.
    [J]. LUNG CANCER, 2013, 80 (01) : 102 - 105
  • [8] A Phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
    Milton, Daniel I.
    Azzoli, Christopher G.
    Heelan, Robert T.
    Venkatraman, Ennapadarn
    Gomez, Jorge E.
    Kris, Mark G.
    Krug, Lee M.
    Pao, William
    Rizvi, Naiyer A.
    Dunne, Megan
    Miller, Vincent A.
    [J]. CANCER, 2006, 107 (05) : 1034 - 1041
  • [9] OPTIMAL 2-STAGE DESIGNS FOR PHASE-II CLINICAL-TRIALS
    SIMON, R
    [J]. CONTROLLED CLINICAL TRIALS, 1989, 10 (01): : 1 - 10
  • [10] Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
    Togashi, Yosuke
    Masago, Katsuhiro
    Fukudo, Masahide
    Tsuchido, Yasuhiro
    Okuda, Chiyuki
    Kim, Young Hak
    Ikemi, Yasuaki
    Sakamori, Yuichi
    Mio, Tadashi
    Katsura, Toshiya
    Mishima, Michiaki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 1089 - 1092
12